The specific attributes of inhaler devices can influence patient use, satisfaction and treatment compliance, and may ultimately impact on clinical outcomes in patients with chronic obstructive ...
AstraZeneca today announced that Duaklir® Genuair® (aclidinium bromide/formoterol fumarate 340/12 mcg) has been granted Marketing Authorisation by the European Commission (EC) to be used as a ...
The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. BRIMICA GENUAIR 340/12 contains the active ingredient aclidinium ...
Duaklir Genuair is a fixed-dose combination of Eklira, a long-acting muscarinic-antagonist, and Mylan, Inc.’s (MYL) Perforomist (formoterol fumarate), a long-acting beta-agonist. Both are individually ...
MISSISSAUGA, ON, Oct. 31, 2013 /CNW/ - Almirall Canada announced the Health Canada approval of Tudorza™ Genuair™ (aclidinium bromide) as a long-term maintenance bronchodilator treatment in patients ...
European regulators have given the all clear to Almirall's Eklira Genuair to help alleviate the symptoms of chronic obstructive pulmonary disease (COPD), hot on the heels of a US green light. European ...
Barcelona, September, 25 2014. - Almirall S.A. (ALM) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion ...
European Commission approves Eklira/Bretaris Genuair as maintenance bronchodilator treatment of COPD
Almirall S.A. (ALM), an international pharma company based on innovation and committed to health, has received the European Commission marketing approval to Eklira/Bretaris Genuair(aclidinium 322µg ...
The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. BRETARIS GENUAIR contains the active ingredient aclidinium bromide.
AstraZeneca today announced that Duaklir® Genuair® (aclidinium bromide/formoterol fumarate 340/12 mcg) has been granted Marketing Authorisation by the European Commission (EC) to be used as a ...
DUAKLIR™ GENUAIR® now available in Canada for the treatment of chronic obstructive pulmonary disease
MISSISSAUGA, ON, Oct. 29, 2015 /CNW/ - AstraZeneca Canada announced today that DUAKLIR ™ GENUAIR ® (aclidinium bromide/formoterol fumarate dihydrate 400/12 μg) is now available in Canada for the ...
Almirall S.A. (ALM) announced today that the European Commission has granted marketing approval to Eklira/Bretaris Genuair ® (aclidinium 322µg twice daily) in all EU member states, plus Iceland and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results